Compare · AVTE vs NVO
AVTE vs NVO
Side-by-side comparison of Aerovate Therapeutics Inc. (AVTE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.28B, about 796.1x AVTE ($246.5M).
- NVO has hit the wire 8 times in the past 4 weeks while AVTE has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 17 for AVTE).
- Company
- Aerovate Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $2.70+1.12%
- $43.97+2.76%
- Market cap
- $246.5M
- $196.28B
- 1M return
- -
- -6.43%
- 1Y return
- -
- -45.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 8
- Recent ratings
- 17
- 25
Aerovate Therapeutics Inc.
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVTE
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- SEC Form 4 filed by Director Lavelle Erin
- SEC Form 4 filed by Director Klein Lawrence Otto
- SEC Form 4 filed by Director Cain Christopher W.
- SEC Form 4 filed by Director Dobmeier Eric
- New insider Fairmount Funds Management Llc claimed ownership of 3,220,368 shares (SEC Form 3)
- SEC Form 3 filed by new insider Lavelle Erin
- New insider Klein Lawrence Otto claimed ownership of 86,215 shares (SEC Form 3)
- SEC Form 3 filed by new insider Cain Christopher W.
- SEC Form 3 filed by new insider Dobmeier Eric
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care